BioCentury | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

...Serotonin 5-HT1A receptor 5-HT2A - Serotonin 5-HT2A receptor ADRA1a - Adrenergic receptor alpha 1a ADRA1b - Adrenergic receptor alpha...
BioCentury | Jun 21, 2019
Company News

June 20 Company Quick Takes: Priority Review for Alexion, Melinta therapies; plus Alimera, Denovo and more

...Sciences Inc. Denovo Biopharma LLC Janssen Johnson & Johnson Melinta Therapeutics Inc. Orion Corp. University of California Berkeley University of California San Francisco Adrenergic receptor alpha...
BioCentury | May 28, 2019
Distillery Therapeutics

Adrenergic receptor inhibitor combo to treat stroke

...Wako, Japan email: monai.hiromu@ocha.ac.jp CONTACT: Hajime Hirase, same affiliaion as above email: hajime.hirase@riken.jp Chris Lieu Riken Adrenergic receptor alpha 1 (ADRA1) Adrenergic receptor alpha...
BioCentury | Apr 11, 2019
Company News

Ocugen to go public via Histogenics reverse merger

Ocugen will reverse merge with Histogenics to form a public company focused on discovering, developing and commercializing therapies for rare eye diseases. Ocugen Inc. (Malvern, Pa.) stockholders will own about 90% of the resulting company,...
BioCentury | Mar 14, 2019
Company News

Tonix's PTSD therapy loses breakthrough therapy designation

...for which Tonix said it observed treatment activity in HONOR. Sandi Wong, Staff Writer Tonix Pharmaceuticals Holding Corp. Adrenergic receptor alpha...
BioCentury | Feb 1, 2019
Clinical News

Eyenovia planning NDA in 1Q20 for microdose ophthalmic solution to induce mydriasis

Eyenovia Inc. (NASDAQ:EYEN) plans to submit an NDA to FDA in 1Q20 for MicroStat to induce mydriasis (dilation of the pupil) after the product met the primary endpoint in the Phase III MIST-1 trial. MicroStat...
BioCentury | Aug 3, 2018
Clinical News

Tonix stops Phase III of PTSD candidate on lack of separation from placebo

...Interim Phase III data Milestone: NA Elizabeth S. Eaton Tonmya (Sublingual TNX-102, TNX-102 SL, cyclobenzaprine) Tonix Pharmaceuticals Holding Corp. Adrenergic receptor alpha...
BioCentury | May 18, 2018
Clinical News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

...not respond to inquiries regarding its launch plans or pricing details. The oral agonist of adrenergic receptor alpha...
...WorldMeds LLC, Louisville, Ky. Product: Lucemyra lofexidine Business: Neurology Chris Lieu BritLofex, Lucemyra, lofexidine Stada Arzneimittel AG US WorldMeds LLC Adrenergic receptor alpha...
BioCentury | May 16, 2018
Company News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

...not respond to inquiries regarding its launch plans or pricing details. The oral agonist of adrenergic receptor alpha...
...rate of new addiction" (see BioCentury Extra, May 14) . Chris Lieu BritLofex, lofexidine Stada Arzneimittel AG US WorldMeds LLC Adrenergic receptor alpha...
BioCentury | Apr 13, 2018
Clinical News

Ocugen reports Phase II data for dry eye disease candidate

...in 3Q18. The product is an ophthalmic nanoemulsion formulation of brimonidine tartrate, a relatively selective adrenergic receptor alpha...
...Molecular target: Adrenergic receptor alpha 2 (ADRA2) Description: Ophthalmic nanoemulsion formulation of brimonidine tartrate, a relatively selective adrenergic receptor alpha...
Items per page:
1 - 10 of 319